Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benkert

Showing results (601-610 of 621) with videos related to

Pageof 63
Sort By:
Journal of Neurology|July 2, 2025
Comparative effectiveness of teriflunomide and ocrelizumab on smoldering activity in multiple sclerosis: an observational study in the Swiss Multiple Sclerosis CohortAlessandro Cagol, Sabine Schaedelin, Mario Ocampo-Pineda, et al.
JAMA Neurology|November 6, 2023
Neurofilament Light Chain Elevation and Disability Progression in Multiple SclerosisAhmed Abdelhak, Pascal Benkert, Sabine Schaedelin, et al.
Annals of Neurology|May 31, 2021
Intrathecal Immunoglobulin M Synthesis is an Independent Biomarker for Higher Disease Activity and Severity in Multiple SclerosisJohanna Oechtering, Sabine Schaedelin, Pascal Benkert, et al.
Journal of Neurology|May 15, 2023
Prognostic performance of blood neurofilament light chain protein in hospitalized COVID-19 patients without major central nervous system manifestations: an individual participant data meta-analysisAhmed Abdelhak, Lorenzo Barba, Michele Romoli, et al.
JAMA Neurology|February 6, 2023
Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple SclerosisStephanie Meier, Eline A J Willemse, Sabine Schaedelin, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 8, 2023
Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosisNicolás Fissolo, Pascal Benkert, Jaume Sastre-Garriga, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|January 3, 2025
Aberrant Complement Activation Is Associated With Structural Brain Damage in Multiple SclerosisJohanna Oechtering, Sabine Anna Schaedelin, Kerstin Stein, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|December 6, 2024
Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data NetworkJohannes Lorscheider, Alessio Signori, Suvitha Subramaniam, et al.
Annals of Clinical and Translational Neurology|August 4, 2025
Serum Neurofilament Light Chain in Multiple Sclerosis: Superiority of Age- and BMI-Corrected Z Scores/Percentiles Over Absolute Cutoff Values for Prediction of Treatment ResponseMaximilian Einsiedler, Aleksandra Maleska Maceski, Sofia Sandgren, et al.
Bioengineering (Basel, Switzerland)|August 29, 2024
Contrast-Enhancing Lesion Segmentation in Multiple Sclerosis: A Deep Learning Approach Validated in a Multicentric CohortMartina Greselin, Po-Jui Lu, Lester Melie-Garcia, et al.
Pageof 63

Showing results (601-610 of 621) with videos related to

Sort By:
Pageof 63
Journal of Neurology|July 2, 2025
Comparative effectiveness of teriflunomide and ocrelizumab on smoldering activity in multiple sclerosis: an observational study in the Swiss Multiple Sclerosis CohortAlessandro Cagol, Sabine Schaedelin, Mario Ocampo-Pineda, et al.
JAMA Neurology|November 6, 2023
Neurofilament Light Chain Elevation and Disability Progression in Multiple SclerosisAhmed Abdelhak, Pascal Benkert, Sabine Schaedelin, et al.
Annals of Neurology|May 31, 2021
Intrathecal Immunoglobulin M Synthesis is an Independent Biomarker for Higher Disease Activity and Severity in Multiple SclerosisJohanna Oechtering, Sabine Schaedelin, Pascal Benkert, et al.
Journal of Neurology|May 15, 2023
Prognostic performance of blood neurofilament light chain protein in hospitalized COVID-19 patients without major central nervous system manifestations: an individual participant data meta-analysisAhmed Abdelhak, Lorenzo Barba, Michele Romoli, et al.
JAMA Neurology|February 6, 2023
Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple SclerosisStephanie Meier, Eline A J Willemse, Sabine Schaedelin, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 8, 2023
Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosisNicolás Fissolo, Pascal Benkert, Jaume Sastre-Garriga, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|January 3, 2025
Aberrant Complement Activation Is Associated With Structural Brain Damage in Multiple SclerosisJohanna Oechtering, Sabine Anna Schaedelin, Kerstin Stein, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|December 6, 2024
Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data NetworkJohannes Lorscheider, Alessio Signori, Suvitha Subramaniam, et al.
Annals of Clinical and Translational Neurology|August 4, 2025
Serum Neurofilament Light Chain in Multiple Sclerosis: Superiority of Age- and BMI-Corrected Z Scores/Percentiles Over Absolute Cutoff Values for Prediction of Treatment ResponseMaximilian Einsiedler, Aleksandra Maleska Maceski, Sofia Sandgren, et al.
Bioengineering (Basel, Switzerland)|August 29, 2024
Contrast-Enhancing Lesion Segmentation in Multiple Sclerosis: A Deep Learning Approach Validated in a Multicentric CohortMartina Greselin, Po-Jui Lu, Lester Melie-Garcia, et al.
Pageof 63